

**Medicaid Preferred Drug List (PDL) Program:
Phase I PDL Annual Review and Review of New Drugs & New Drug Classes
Pharmacy and Therapeutics Committee Meeting
Monday, October 31, 2005
9:00 a.m., DMAS Board Room
REVISED DRAFT AGENDA**

- **Welcome and Introductions** **Patrick W. Finnerty, Director**

- **Comments from the Secretary of Health and Human Resources** **The Honorable Jane H. Woods,
Secretary of Health and Human Resources**

- **Comments from the Chairperson** **Randy Axelrod, M.D., Chairman**

- **Acceptance of Minutes** **P&T Committee Members**
From June 8, 2005 and August 31, 2005 P&T Meetings

- **Drug Class Discussions** **P&T Committee Members**

Review of New Drugs in PDL Classes

- Factive[®] – Quinolones
- Zmax[™] – Macrolides
- Clarithromycin (Generic Biaxin[®])-Macrolides
- Actonel[®] with Calcium CO-PACK-Bisphosphonates

Phase I PDL Annual Review

- HMG CoA Reductase Inhibitors (Statins)
- Cox-2 Inhibitors
- Proton Pump Inhibitors (PPIs)
- Angiotensin Receptor Blockers (ARBs)
(formerly named Angiotensin Receptor Antagonists)
- Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
- Inhaled Corticosteroids
- Nasal Steroids
- Beta Adrenergics
- COPD- Anticholinergics
(formerly included with Beta Adrenergics)
- Beta Blockers
- Calcium Channel Blockers
- H2 Antagonists
- Second Generation Antihistamines (LSAs)
- Benzodiazepine Sedative Hypnotics
(formerly included with Sedative Hypnotics)
- Other Sedative Hypnotics
(formerly included with Sedative Hypnotics)

Potential New PDL Drug Classes

- Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
- Phosphodiesterase 5 Inhibitor for Pulmonary Arterial Hypertension
- **Confidential Meeting**
- **Criteria Discussion of New Drugs**
- **Criteria Discussions for Phase I PDL Drug Classes**
- **Criteria Discussions for New Drug Classes**
 - Electrolyte Depleters
 - Urinary Tract Antispasmodics
 - Topical Immunomodulators
 - Lipotropics Non-Statins: Fibric Acid
 - Lipotropics Non-Statins: Niacin Derivatives
 - *Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
 - *Phosphodiesterase 5 Inhibitor for Pulmonary Arterial Hypertension
- **Next Meeting – TBD**

DMAS and First Health Services Corporation Staff

P&T Committee Members

Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information

**Randy Axelrod, M.D., Chairman
P&T Committee Members**

**Randy Axelrod, M.D., Chairman
P&T Committee Members**

**Randy Axelrod, M.D., Chairman
P&T Committee Members**

Randy Axelrod, M.D., Chairman

**Criteria discussions will be held for these classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions*

Oral presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on **only** the drug classes subject to annual review and specific new drugs that are listed on the Agenda. All presentations for the annual review of Phase I PDL drug classes and new drugs in Phase II & III drug classes must be newly published (October 2004 - present), clinical in nature and based on scientific material. No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

If you are interested in providing specific clinical drug information, please submit an outline of discussion points, clinical references within the stated guidelines above, your written request to speak, and the name of the presenter. Please send information to pdlinput@dmavirginia.gov by COB Wednesday, October 5, 2005.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmavirginia.gov by COB Wednesday, October 5, 2005.

Update October 7, 2005:

The P&T Committee will now accept presentation requests and written comments for Phosphodiesterase 5 Inhibitors for Erectile Dysfunction and Pulmonary Arterial Hypertension as part of their drug class discussions at the October 31st meeting. The deadline for presentation requests and written comments for these classes ONLY has been extended to COB Friday, October 14, 2005. Please see the guidelines below for Phosphodiesterase 5 Inhibitor drug classes:

Oral presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information for Phosphodiesterase 5 Inhibitor drug classes on listed on the Agenda. All presentations for these drug classes under consideration for PDL eligibility must have been published within the past three years (June 2002 - present), clinical in nature and based on scientific material. No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

If you are interested in providing specific clinical drug information, please submit an outline of discussion points, clinical references within the stated guidelines above, your written request to speak, and the name of the presenter. Please send information to pdlinput@dmass.virginia.gov by COB Friday, October 14, 2005.

Written information/comments: The P&T Committee will also accept written comments for consideration for the Phosphodiesterase 5 Inhibitor drug classes on listed on the Agenda. Please send statements to pdlinput@dmass.virginia.gov by COB Friday, October 14, 2005.